Land: Vereinigte Staaten
Sprache: Englisch
Quelle: NLM (National Library of Medicine)
Famotidine (UNII: 5QZO15J2Z8) (Famotidine - UNII:5QZO15J2Z8)
Dispensing Solutions, Inc.
Famotidine
Famotidine 40 mg
ORAL
PRESCRIPTION DRUG
Famotidine is indicated in: - Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. - Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - Short term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). Famotidine is also indicated for the short term treatment of esophag
Famotidine Tablets USP (white round tablets) containing 20mg of famotidine and engraved with . Bottle of 30 (NDC 61442-121-30) Bottle of 100 (NDC 61442-121-01) Bottle of 500 (NDC 61442-121-05) Bottle of 1,000 (NDC 61442-121-10) Famotidine Tablets USP (white round tablets) containing 40mg of famotidine and engraved with . Bottle of 30 (NDC 61442-122-30) Bottle of 100 (NDC 61442-122-01) Bottle of 500 (NDC 61442-122-05) Bottle of 1,000 (NDC 61442-122-10) Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Manufactured and Distributed by: Carlsbad Technology, Inc. Carlsbad, CA 92008 Revised: 06/12 CTI-12 Rev. C
Abbreviated New Drug Application
FAMOTIDINE- FAMOTIDINE TABLET DISPENSING SOLUTIONS, INC. ---------- FAMOTIDINE TABLETS USP DESCRIPTION The active ingredient in famotidine, is a histamine H -receptor antagonist. Famotidine is _N'_- (aminosulfonyl)-3-[[[2-[(diamino-methylene)amino]-4- thiazolyl]methyl]thio]propanimidamide. The empirical formula of famotidine is C H N O S and its molecular weight is 337.45. Its structural formula is: Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. Each tablet for oral administration contains either 20 mg or 40 mg of famotidine and the following inactive ingredients: hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycolate, sodium starch glycolate, modified corn starch (pregelatinized starch), talc, triacetin, titanium dioxide. CLINICAL PHARMACOLOGY IN ADULTS GI EFFECTS Famotidine is a competitive inhibitor of histamine H -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output. In normal volunteers and hypersecretors, famotidine inhibited basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours. Duration of inhibition of secretion by doses of 20 and 40 mg was 10 to 12 hours. Single evening oral doses of 20 and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects. Lesen Sie das vollständige Dokument